Drugs / MBX-2044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00422487 | Oct 2006 → Aug 2007 | type 2 diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBX-2044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422487 ↗ |
| Route | Oral | “When Administered Orally” NCT00422487 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma modulator” CHEMBL3545020 ↗ |